SHR-A1811 + Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan

Phase 3Recruiting

1 views this week 0 watching⚡ Active🧬Featured in Oncology Pipeline Watch

Interest: 47/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Conditions

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Trial Timeline

Jan 9, 2024 → Jun 30, 2027

NCT ID

NCT06123494

About SHR-A1811 + Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan

SHR-A1811 + Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06123494. Target conditions include HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.

What happened to similar drugs?

0 of 14 similar drugs in HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma were approved

Approved (0) Terminated (0) Active (14)

🔄TrastuzumabCelltrionPhase 3

🔄Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3

🔄Trastuzumab deruxtecan + Placebo + Taxane + Pertuzumab + TrastuzumabDaiichi SankyoPhase 3

🔄DS-8201a + T-DM1Daiichi SankyoPhase 3

🔄SHR-A1811 Injection + SHR-A1811 Injection ； Pertuzumab Injection + Trastuzumab Injection；Pertuzumab Injection ； Docetaxel InjectionJiangsu Hengrui MedicinePhase 3

🔄SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab InjectionJiangsu Hengrui MedicinePhase 3

🔄Pyrotinib + Placebo Oral Tablet + Trastuzumab + DocetaxelJiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06123494	Phase 3	Recruiting	Jan 9, 2024	Jun 30, 2027	HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Competing Products

20 competing products in HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

See all competitors

Product	Company	Stage	Hype Score
ALT-P7 (HM2-MMAE)	Alteogen	Phase 1	29
CT-0508 + Pembrolizumab	Carisma Therapeutics	Phase 1	23
CT-0525	Carisma Therapeutics	Phase 1	23
Trastuzumab	Celltrion	Phase 3	40
Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + Gemcitabine	Chugai Pharmaceutical	Phase 3	40
YH32367	Yuhan	Phase 1/2	39
Trastuzumab deruxtecan	Daiichi Sankyo	Pre-clinical	33
Trastuzumab deruxtecan	Daiichi Sankyo	Pre-clinical	26
Trastuzumab deruxtecan	Daiichi Sankyo	Pre-clinical	33
Trastuzumab deruxtecan (T-DXd)	Daiichi Sankyo	Pre-clinical	33
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	42
Trastuzumab deruxtecan + Placebo + Taxane + Pertuzumab + Trastuzumab	Daiichi Sankyo	Phase 3	44
DS-8201a + T-DM1	Daiichi Sankyo	Phase 3	44
Pertuzumab + Trastuzumab + eribulin	Eisai	Phase 2	27
Tucatinib 150 MG + Trastuzumab + Capecitabine	Biocon	Phase 2	42
SHR-A1811 Injection + SHR-A1811 Injection ； Pertuzumab Injection + Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection	Jiangsu Hengrui Medicine	Phase 3	44
Pyrotinib	Jiangsu Hengrui Medicine	Pre-clinical	22
SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab Injection	Jiangsu Hengrui Medicine	Phase 3	47
Pyrotinib + Placebo Oral Tablet + Trastuzumab + Docetaxel	Jiangsu Hengrui Medicine	Phase 3	40
pyrotinib tablet + Montmorillonite Power + Loperamide	Jiangsu Hengrui Medicine	Phase 1	29